Vor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by HC Wainwright

Vor Biopharma (NYSE:VORGet Rating)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Monday, TipRanks reports. They currently have a $26.00 price objective on the stock.

Several other equities analysts also recently commented on the stock. JMP Securities lowered their target price on shares of Vor Biopharma from $30.00 to $15.00 in a research report on Friday. Zacks Investment Research raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Friday, March 18th. B. Riley decreased their target price on Vor Biopharma from $60.00 to $46.00 in a research report on Monday, January 24th. Barclays dropped their price target on shares of Vor Biopharma from $56.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, March 21st. Finally, The Goldman Sachs Group started coverage on shares of Vor Biopharma in a report on Wednesday, April 27th. They set a “neutral” rating and a $6.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $24.47.

NYSE:VOR traded down $0.06 during mid-day trading on Monday, reaching $4.16. The stock had a trading volume of 790 shares, compared to its average volume of 96,663. The stock has a market cap of $156.05 million, a P/E ratio of -1.98 and a beta of -0.38. The business’s 50 day moving average is $6.33 and its 200 day moving average is $9.64. Vor Biopharma has a fifty-two week low of $4.13 and a fifty-two week high of $23.96.

Vor Biopharma (NYSE:VORGet Rating) last posted its earnings results on Monday, March 14th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.06. Research analysts predict that Vor Biopharma will post -2.41 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Johnson & Johnson bought a new position in Vor Biopharma in the third quarter worth $16,851,000. OUP Management Co. LLC bought a new position in shares of Vor Biopharma during the 4th quarter worth about $4,354,000. BlackRock Inc. boosted its position in shares of Vor Biopharma by 46.1% during the 3rd quarter. BlackRock Inc. now owns 1,130,038 shares of the company’s stock valued at $17,719,000 after acquiring an additional 356,413 shares in the last quarter. Paradigm Biocapital Advisors LP increased its stake in Vor Biopharma by 42.1% in the first quarter. Paradigm Biocapital Advisors LP now owns 894,404 shares of the company’s stock valued at $5,402,000 after acquiring an additional 265,062 shares during the period. Finally, Laurion Capital Management LP raised its position in Vor Biopharma by 30.4% in the fourth quarter. Laurion Capital Management LP now owns 857,308 shares of the company’s stock worth $9,962,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 83.11% of the company’s stock.

Vor Biopharma Company Profile (Get Rating)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

Featured Stories

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.